Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Martinez-Castelao

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|June 11, 2002
Conivaptan (Yamanouchi)Alberto Martinez-Castelao
Transplantation Reviews (Orlando, Fla.)|December 6, 2011
Proteinuria: detection and role in native renal disease progressionJose Luis Gorriz, Alberto Martinez-Castelao
International Urology and Nephrology|August 15, 2014
Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA StudyAleix Cases, José Portolés, Jordi Calls, et al.
Renal Failure|December 25, 2009
Anemia development and cardiovascular risk management in nonanemic stage 3 chronic kidney diseaseJosé Portolés, Alberto Martinez Castelao, Jose Luis Gorriz, et al.
Clinical Kidney Journal|July 11, 2018
Impact of immunosuppressive therapy on arterial stiffness in kidney transplantation: are all treatments the same?Edoardo Melilli, Anna Manonelles, Nuria Montero, et al.
Kidney International. Supplement|November 2, 2002
Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European UnionWilliam C Gerth, Giuseppi Remuzzi, GianCarlo Viberti, et al.
BMC Nephrology|January 9, 2013
The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney diseaseJosé Portolés, Jose Luis Gorriz, Esther Rubio, et al.
Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia|November 26, 2016
Maps of systematic variation in renal replacement therapy in Catalonia (2002-2012)Cristian Tebé Condomí, Emma Arcos, Jordi Comas, et al.
Journal of Nephrology|July 6, 2010
Design and patient characteristics of ESHOL study, a Catalonian prospective randomized studyFrancisco Maduell, Francesc Moreso, Mercedes Pons, et al.
Clinical Kidney Journal|June 15, 2019
Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?Beatriz Fernandez-Fernandez, Raul Fernandez-Prado, Jose Luis Górriz, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Current Opinion in Investigational Drugs (London, England : 2000)|June 11, 2002
Conivaptan (Yamanouchi)Alberto Martinez-Castelao
Transplantation Reviews (Orlando, Fla.)|December 6, 2011
Proteinuria: detection and role in native renal disease progressionJose Luis Gorriz, Alberto Martinez-Castelao
International Urology and Nephrology|August 15, 2014
Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA StudyAleix Cases, José Portolés, Jordi Calls, et al.
Renal Failure|December 25, 2009
Anemia development and cardiovascular risk management in nonanemic stage 3 chronic kidney diseaseJosé Portolés, Alberto Martinez Castelao, Jose Luis Gorriz, et al.
Clinical Kidney Journal|July 11, 2018
Impact of immunosuppressive therapy on arterial stiffness in kidney transplantation: are all treatments the same?Edoardo Melilli, Anna Manonelles, Nuria Montero, et al.
Kidney International. Supplement|November 2, 2002
Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European UnionWilliam C Gerth, Giuseppi Remuzzi, GianCarlo Viberti, et al.
BMC Nephrology|January 9, 2013
The development of anemia is associated to poor prognosis in NKF/KDOQI stage 3 chronic kidney diseaseJosé Portolés, Jose Luis Gorriz, Esther Rubio, et al.
Nefrologia : Publicacion Oficial De La Sociedad Espanola Nefrologia|November 26, 2016
Maps of systematic variation in renal replacement therapy in Catalonia (2002-2012)Cristian Tebé Condomí, Emma Arcos, Jordi Comas, et al.
Journal of Nephrology|July 6, 2010
Design and patient characteristics of ESHOL study, a Catalonian prospective randomized studyFrancisco Maduell, Francesc Moreso, Mercedes Pons, et al.
Clinical Kidney Journal|June 15, 2019
Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?Beatriz Fernandez-Fernandez, Raul Fernandez-Prado, Jose Luis Górriz, et al.
Pageof 3